dose response curves for capivasertib (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress dose response curves for capivasertib

The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines <t>(A)</t> <t>Dose-response</t> curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .

Dose Response Curves For Capivasertib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 128 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dose+response/Capivasertib/pmc13106976-441-0-4
Average 97 stars, based on 128 article reviews

dose response curves for capivasertib - by Bioz Stars, 2026-10

97/100 stars

Images

1) Product Images from "Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss"

Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss

Journal: Cell Reports Methods

doi: 10.1016/j.crmeth.2026.101370

The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .

Figure Legend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .

Techniques Used: In Vivo, In Vitro, Concentration Assay

CCK-8 Assay:

Article Title: Calcium-modulated GJB6-GRHL3 positive feedback loop attenuates ESCC progression through AKT signaling pathway inhibition.
Article Snippet: .. The CCK-8 assay kit was purchased from Boster Biotech (Wuhan, China); 18α-glycyrrhetinic acid (18αGA) was acquired from Sigma-Aldrich (St. Louis, MO, USA) and MedChemExpress (MCE; Monmouth Junction, NJ, USA); lucifer yellow CH dipotassium salt, all-trans-retinoic acid (ATRA), BATPA-AM, MK- AR TI CL E IN P RE SS 2206 dihydrochloride and capivasertib (AZD5363) were all obtained from MCE. .. CRISPR Cas9 screening in vitro A crRNA library targeting 406 genes was applied to screen for CNA driver genes related to ESCC (Dharmacon, Boston, USA).

Recombinant:

Article Title: Integrated multi-omics profiling of treatment-naive cervix uteri premalignant lesions and cervical squamous cell carcinoma reveals ecosystem and drivers underlying cervical cancer progression
Article Snippet: .. The reagents we used in this study were as follows: PI3Kα inhibitor alpelisib (HY-15244, MedChemExpress), pan-AKT inhibitor capivasertib (HY-15431, MedChemExpress), mTOR1 inhibitor everolimus (HY-10218, MedChemExpress), cycloheximide (HY-12320, MedChemExpress), FGF1 receptor inhibitor PD161570 (HY-100434, MedChemExpress), proteasome and calpain inhibitor MG132 (HY-13259, MedChemExpress), autophagy inhibitor 3-Methyladenine (HY-19312, MedChemExpress), Recombinant human ISG15 protein (I245-31H, Sino Biological), Recombinant human FGF1 protein (ab91374, abcam). .. The following antibodies were used in our study: anti-ISG15 (ab285367, abcam), anti-PTGDS (ab182141, abcam), anti-CLDN1(ab211737, abcam), anti-GAPDH (#HRP-60004, Proteintech), anti-IGFBP7 (ab171085, abcam), Anti-IGKC Mouse monoclonal antibody ( HA601099 , Huabio), Anti-GNLY/Granulysin (ab241333, abcam), Anti-Collagen III (ab6310, abcam), Anti-Von Willebrand Factor (ab201336, abcam), Anti-FGF1 (ab207321, abcam), Anti-FGFR1 (phospho Y654, ab59194, abcam), Anti-FGF Receptor 1 (9740S, CST), Anti-p-AKT (Thr308) (13038, CST), Anti-p-AKT (Ser473) (4060, CST), Anti-AKT (4691, CST), Anti-p-mTOR (Ser2448) (5536, CST), Anti-mTOR (2983, CST), Anti-PI3K p85 (4257, CST), Anti-PI3K p85 Y458/p55 Y199 (17366S, CST), Anti-Ki67 (ab16667, abcam), Anti-CDKN2A/p16INK4a (ab241543, abcam), Anti-ubiquitin (10201-2-AP, Proteintech).

other:

Article Title: PPP2R5B regulates ANPEP expression and TGEV entry via dephosphorylation of HSF1 at Ser304/Ser308
Article Snippet: Cells were treated with specific inhibitors, including LB-100 (MCE, HY-15431), Compound C (MCE, HY-13418A), AICAR (MCE, HY-13417), and Capivasertib (MCE, HY-15431), prepared as stock solutions and diluted to working concentrations prior to use.

Western Blot:

Article Title: Olfactomedin 4 orchestrates TGF-β/CEACAM6 axis, promoting cell-autonomous epithelial to mesenchymal transition during gallbladder epithelium carcinogenesis
Article Snippet: For rescue experiments, OLFM4-knockdown GBC cells were incubated with recombinant human TGF-β protein (Cat No. HZ-1011, ProteinTech) with different doses and time series indicated. .. To explore the role of p-AKT in CEACAM6/EMT cascade, p-AKT inhibitor (Capivasertib, Cat No. HY-15431, MCE) was employed to treat GBC cells at different concentrations and immunoblotting was performed to examine the expression of EMT markers. ..

Expressing:

Radial Immuno Diffusion:

Article Title: Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer.
Article Snippet: Other pharmacological inhibitors used throughout the study include ALW II-41-27-EPHA2 inhibitor (E0614, SelleckChem), RI-1-RAD51 inhibitor 130 (HY-15317, MCE), Trametinib (S2673, Selleckchem), SIS3-SMAD3 inhibitor (S3552, SelleckChem), CC90001-JNK inhibitor (HY-138304, MCE) and Copanlisib-PI3K inhibitor (HY-15346, MCE). .. Y-27632 2HCl- Jo urn al Pr e-p roo f 6 ROCK1/2 inhibitor (S1049, SelleckChem), Ralimetinib- p38 inhibitor (HY-13241A, MCE), CapivasertibAKT inhibitor (HY-15431, MCE), Z-VAD-FMK – Pan-caspase inhibitor (HY-16658, MCE), Necrostatin-1- Necroptosis inhibitor (HY-15760, MCE), Dasatinib- SRC inhibitor (HY-10181, MCE) and IMD-0354- IKK 135 inhibitor (HY-10172, MCE). ..

Review